

Correction: *Clinical characteristics, time course, treatment and outcomes of patients with immune checkpoint inhibitor-associated myocarditis*

Puzanov I, Subramanian P, Yatsynovich YV, *et al.* Clinical characteristics, time course, treatment and outcomes of patients with immune checkpoint inhibitor-associated myocarditis. *J Immunother Cancer* 2021;9:e002553. doi: 10.1136/jitc-2021-002553

This article has been corrected since it was first published. Author name has been corrected to 'Jerome J Schentag'.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See <http://creativecommons.org/licenses/by-nc/4.0/>.

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

J Immunother Cancer 2021;9:e002553corr1. doi:10.1136/jitc-2021-002553corr1

